FDA Fully Approves Alzheimer’s Drug Leqembi

This traditional approval follows previously fast-tracked authorization. The Food and Drug Administration (FDA) has approved Leqembi for the treatment of Alzheimer’s disease. The FDA included a safety warning…

Read More

Congress Issues Report on FDA’s Aduhelm Approval

House committees are concerned with the atypical protocol that was followed. Two House committees published a report at the end of the year highlighting the irregular means the…

Read More

HHS Secretary Orders Alzheimer’s Drug Price be Reassessed

Response to Medicare’s announcement of Aduhelm price hike. Secretary of Health and Human Services Xavier Becerra ordered a reassessment of Medicare’s proposed pricing for Aduhelm on Monday. The…

Read More

FDA Calls for Investigation into Alzheimer’s Drug

Probe comes after three members of the drug advisory board resigned in protest. On Friday, Food and Drug Administration Acting Commissioner Dr. Janet Woodcock called for an independent…

Read More

FDA Accelerates Alzheimer Drug

Some “residual uncertainties” in test results acknowledged. This past week, the U.S. Food and Drug Administration approved Biogen’s new drug, Aduhelm, for treating Alzheimer’s disease, which showed in…

Read More

NIH Invests in Advanced Research for Alzheimer’s

Entering into public-private partnership to expand therapies and interventions. The National Institutes of Health announce the launch of the next version of the program that expands scientific research…

Read More
Back to top